Bristol, 2seventy Abecma OKd for Multiple Myeloma

 Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial, with a 51% reduction in risk of disease progression or death and a well-established safety profile

Expanded approval brings this personalized CAR T cell therapy to more patients with relapsed or refractory multiple myeloma earlier in their treatment journey as a one-time infusion offering meaningful treatment-free intervals when responding to therapy

Abecma is now approved in the U.S., Japan, Switzerland and the EU for earlier use for triple-class exposed relapsed and/or refractory multiple myeloma, underscoring BMS’ commitment to delivering Abecma globally, with consistently high manufacturing success rates and continuous increases in capacity

https://www.biospace.com/article/releases/u-s-fda-approves-bristol-myers-squibb-and-2seventy-bio-s-abecma-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-two-prior-lines-of-therapy/